GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chemomab Therapeutics Ltd (STU:2QV0) » Definitions » Short Percentage of Float

Chemomab Therapeutics (STU:2QV0) Short Percentage of Float


View and export this data going back to 2021. Start your Free Trial

What is Chemomab Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Chemomab Therapeutics's Short Percentage of Float

For the Biotechnology subindustry, Chemomab Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chemomab Therapeutics's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chemomab Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Chemomab Therapeutics's Short Percentage of Float falls into.


;
;

Chemomab Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chemomab Therapeutics Ltd (STU:2QV0) » Definitions » Short Percentage of Float
Comparable Companies
BCAB QTTB ABP ALLK ABVC MURA LSTA ENLV CVM FNCH VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
CMMB:USA
Address
Kiryat Atidim, Building 7, Tel Aviv, ISR, 6158002
Website
https://www.chemomab.com
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.

Chemomab Therapeutics Headlines

No Headlines